WO2015020545A2 - New derivatives of n-[(phenoxy)ethoxy]alkylaminoalkanols and their use for preparation of drugs - Google Patents

New derivatives of n-[(phenoxy)ethoxy]alkylaminoalkanols and their use for preparation of drugs Download PDF

Info

Publication number
WO2015020545A2
WO2015020545A2 PCT/PL2014/050047 PL2014050047W WO2015020545A2 WO 2015020545 A2 WO2015020545 A2 WO 2015020545A2 PL 2014050047 W PL2014050047 W PL 2014050047W WO 2015020545 A2 WO2015020545 A2 WO 2015020545A2
Authority
WO
WIPO (PCT)
Prior art keywords
ethoxy
amino
ethyl
dimethylphenoxy
chh
Prior art date
Application number
PCT/PL2014/050047
Other languages
French (fr)
Other versions
WO2015020545A3 (en
Inventor
Anna Waszkielewicz
Agnieszka GUNIA
Henryk Marona
Original Assignee
Uniwersytet Jagielloński
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uniwersytet Jagielloński filed Critical Uniwersytet Jagielloński
Publication of WO2015020545A2 publication Critical patent/WO2015020545A2/en
Publication of WO2015020545A3 publication Critical patent/WO2015020545A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Definitions

  • the subject of the invention constitutes new derivatives of N- [(phenoxy)ethoxy]alkylaminoalkanols, which according to the invention possess pharmacological activity, in particular in therapy and/or prophylaxis of disorders and symptoms with neurological etiology.
  • Epilepsy is defined as occurrence without identifiable cause recurrent epileptic seizures, while neuropathic pain is connected with abnormal function of neurons.
  • Common pathomechanisms of those two disorders, i.e. pathological changes occurring within nervous system enable simultaneous development of drugs for those kind of disorders.
  • Both epilepsy and neuropathic pain despite available pharmacotherapy, remain insufficiently treated in significant groups of patients. It is estimated that about 30% of epilepsy patients still suffer from seizures, while among patients experiencing partial seizures (simple, complex, and secondarily generalized) the percentage is even higher and reaches 40%. Neuropathic pain is insufficiently treated in about 50% of patients.
  • antiepileptic drugs can be divided into following chemical groups: hydantoin derivatives, barbituric acid derivatives, 2,5-pyrrolidinedione derivatives, iminostilbene derivatives, 1,4- and 1,5-benzodiazepines derivatives, valproic acid derivatives, oxazolidinone derivatives, acetylurea derivatives, sulfonamide derivatives, GABA-analogues and other drugs with various structures.
  • Patent EP1809273 lists several various drugs available for the treatment of epileptic seizures. There are older drugs such as phenytoin (diphenylhydantoin), sodium valproate, and carbamazepine, as well as newer drugs such as felbamate (derivative of carbamic acid), gabapentin and pregabalin (derivatievs of carboxylic acid), topiramate, and tiagabin.
  • phenytoin diphenylhydantoin
  • sodium valproate sodium valproate
  • carbamazepine carbamazepine
  • felbamate derivative of carbamic acid
  • gabapentin and pregabalin derivatievs of carboxylic acid
  • topiramate and tiagabin.
  • Patent PL211939 describes buthylmethylaminoethyltiazophenols.
  • Patent US41 1851 1A describes aryloxyaminobutanols.
  • Aminoalkanols for example l-isopropylamino-3-(naphtyloxy)-2-propanol [J. W. Black, et al., Lancet, 1, 1080 (1964)] acting as potent ⁇ -inhibitor, or alkyl ethers of 3-amino-l-phenoxy-2- propanol showing stimulating effect on central nervous system were described in [J W. Black, et al ., Lancet, 1, 1080 (1964)].
  • Patent PL212489 describes phenoxyalkylaminoalkanols. Those compounds influence the stabilization of functional membrane potential of cells possessing their own electrical function, including nervous cells, what results in possessing potential activity in nervous system disorders.
  • N- [(phenoxy)ethoxy]alkylaminoalkanols similary to phenoxyalkylaminoalkanols are characterized by beneficial pharmacological properties, especially in the treatment and/or prophylaxis of disorders and symptoms with neurological etiology, such as epilepsy and pain. They possess significantly more selective binding to sigma receptors when compared to other tested receptors. Such properties correlate with safer usage of the drugs in pharmacotherapy and decreased number of adverse effects.
  • the main subject of the solution presented within current invention constitutes N- [(phenoxy)ethoxy]alkylaminoalkanols with general structure 1.
  • R2 is aminoalkanol selected from the following: (R,S)-2-aminopropan-l-ol; (R)-2- aminopropan-l-ol; (S)-2-aminopropan-l-ol; (R, S)-2-aminobutan- 1 -ol, (R)-2-aminobutan-l-ol, (S)- 2-aminobutan-l-ol, trans-(D,L)-2-aminocyclohexanol; trans-4-aminocyclohexanol; (R,S)-2-amino- 1-phenyloethanol; 4-hydroxypiperidine, and their accepted for usage in pharmacotherapy salts and pro-drugs.
  • Compounds selected according to present invention are presented in Table 1 below.
  • Rl constitutes (CH 3 ) 2 , (CH 3 ) 3 , or CI and CH 3
  • R2 constitutes aminoalkanol selected from the following: (R,S)-2- aminopropan-l-ol, (R)-2-aminopropan-l-ol, (S)-2-aminopropan-l-ol, (R, S)-2-aminobutan- 1 -ol, (R)-2-aminobutan-l-ol, (S)-2-aminobutan-l-ol, trans-(D,L)-2-aminocyclohexanol, trans-4- aminocyclohexanol, (R,S)-2-aminol-phenylethanol, 4-hydroxypiperidine, and their possible salts accepted for the usage in pharmacotherapy, for the preparation of drug
  • Example 1 The detailed description of synthesis of intermediate products and subject compounds.
  • Example 1.1 Synthesis of 2,6-dimethyl-; 2,3-dimethyl-; 2,4-dimethyl-; 2,4,6,-trimethyl-; 2- chlor-6-methyl- phenoxyethoxyethanol.
  • Example 1.2 Synthesis of 2,6-dimethyl-; 2,3-dimethyl-; 2,4-dimethyl-; 2,4,6,-trimethyl-; 2- chlor-6-methyl- phenoxyethoxyethyl bromides.
  • reaction mixture was filtered, and filtrate was evaporated under reduced pressure to obtain oily residue, then 50 mL of water and 10% HC1 were added to obtain acidic pH under the control of universal indicator paper and activated charcoal was added afterwards.
  • the mixture was refluxed for a while.
  • the mixture was filtered, and the filtrate was alkalified with 10% NaOH to obtain crude base, which was afterwards extracted with toluene.
  • Organic layer was dried over anhydrous Na 2 S0 4 , and the organic solvent was evaporated to obtain oily residue, from which product was crystallized by means of «-hexane.
  • Some compounds were converted into hydrochlorides using the ethanol solution of HC1. Hydrochlorides were crystallized with acetone.
  • T 100-102°C; C ca ic/Cf 0 und 65.23/65.06; H calc /Hf 0U n d 6.91/6.83; N ca i c /Nf 0 und 4.00/4.00
  • 6-Hz test belongs to the animal models of resistant seizures, and activity shown in that test is considered as good predictor for efficacy in psychomotor and focal seizures in humans.
  • the activity on 6-Hz test means moreover possible activity in inhibition of so called epileptogenesis, which is development of epilepsy as a disorder.
  • Activity in pilocarpine test corresponds with prevention of status epilepticus.
  • Activity in formalin test corresponds with inhibition of pain with neurogenic etiology (first phase) and/or pain with inflammatory etiology (second phase) [Bialer, M; White, H. S. Key factors in the discovery and development of new antiepileptic drugs. Nature Rev Drug Discov. 2010,9, 68-82; Loscher, W. Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure 201 1, 20, 359-368].
  • the first phase of evaluation of activity constituted screening in MES and scMet tests. Additionally evaluation of neurotoxicity was conducted in order to establish possible adverse effects from nervous system caused by tested substances. The tests were performed in Carworth Farms 1 mice (intraperitoneal administration, i.p.) and Spague-Dawley rats (oral administration, p.o. and intraperitoneal administration, i.p)
  • mice In mice the test of rotating rod (rotorod test) was performed. In the test the knurled plastic rod rotating 6 times per minute was used. In normal conditions mice are able to remain on rod for long time. If the animal is not able to remain on the rod in every of 3 trials of 1 minute duration it is assumed that the substance caused neurotoxicity.
  • MES test for provoking the seizures electric current was used at 60 Hz and 50 mA (in mice) or 150 mA (in rats) and delivered for 0.2 s via corneal electrodes. The compound is classified as active when it protects from occurring of characteristic hindlimb extension. It is generally accepted that MES test enables verification of anticonvulsant activity in tonic-clonic generalized seizures [http://www.ninds.nih.gov/research/asp/testdesc.htm; White, H. S.; Woodhead, J. H.; Wilcox, K. S.; Stables, J. P.; Kupferberg, H. J.; Wolf, H. H. D. Discovery and preclinical development of antiepileptic drugs.
  • 6-Hz test is conducted in mice.
  • For the provoking the seizures electric current at frequency of 6 Hz and 22, 32, or 44 mA delivered for 3 s via corneal electrodes is used. Protection is defined as remaining the normal activity for 10 s after stimulation [http://www.ninds.nih.gov/research/asp/testdesc.htm; White, H. S.; Woodhead, J. H.; Wilcox, K. S.; Stables, J. P.; Kupferberg, H. J.; Wolf, H. H. D. Discovery and preclinical development of antiepileptic drugs.
  • Formalin test is conducted in mice.
  • the test covers the administration of formalin to hindlimb of the animal, what causes the licking of the place of administration.
  • the total time of licking is considered as corresponding to the intensity of pain sensation experienced by the animal. It is characteristic, that there are two phases of the test.
  • the first phase (acute) is about 10 minutes long and corresponds to the direct stimulation of peripheral sensor and pain neurons
  • the second phase (inflammatory) develops as the response of liberation of inflammatory mediators from impaired tissues and nerves' endings.
  • the activity in that phase corresponds with beneficial effect in neuropathic pain.
  • Simultaneously control tests are performed which involve administration to other animals solvent alone (e.g. methylcellulose).

Abstract

The invention discloses new derivatives of N-[(phenoxy)ethoxy]alkylaminoalkanols with the structure which show pharmacological activity, especially in therapy and/or prophylaxis disorders and/or symptoms withneurological etiology.

Description

New derivatives of N-[(phenoxy)ethoxy]alkylaminoalkanols and their use for preparation of drugs
The subject of the invention constitutes new derivatives of N- [(phenoxy)ethoxy]alkylaminoalkanols, which according to the invention possess pharmacological activity, in particular in therapy and/or prophylaxis of disorders and symptoms with neurological etiology.
Among most frequent disorders of neurological system there are epilepsy and neuropathic pain. Epilepsy is defined as occurrence without identifiable cause recurrent epileptic seizures, while neuropathic pain is connected with abnormal function of neurons. Common pathomechanisms of those two disorders, i.e. pathological changes occurring within nervous system enable simultaneous development of drugs for those kind of disorders. Both epilepsy and neuropathic pain, despite available pharmacotherapy, remain insufficiently treated in significant groups of patients. It is estimated that about 30% of epilepsy patients still suffer from seizures, while among patients experiencing partial seizures (simple, complex, and secondarily generalized) the percentage is even higher and reaches 40%. Neuropathic pain is insufficiently treated in about 50% of patients. [Banerjee, P .N.; Filippi, D.; Allen Hauser, W. The descriptive epidemiology of epilepsy-a review. Epilepsy Res. 2009, 85, 31-45; Waszkielewicz A. M., Gunia A., Sloczynska K ., Marona H. : Evaluation of anticonvulsants for possible use in neuropathic pain. Curr Med Chem. 2011, 18, 4344-4358; Brodie, M.J. Management strategies for refractory localization-related seizures. Epilepsia 2001, 42 Suppl 3, 27-30],
Currently used antiepileptic drugs can be divided into following chemical groups: hydantoin derivatives, barbituric acid derivatives, 2,5-pyrrolidinedione derivatives, iminostilbene derivatives, 1,4- and 1,5-benzodiazepines derivatives, valproic acid derivatives, oxazolidinone derivatives, acetylurea derivatives, sulfonamide derivatives, GABA-analogues and other drugs with various structures.
Patent EP1809273 lists several various drugs available for the treatment of epileptic seizures. There are older drugs such as phenytoin (diphenylhydantoin), sodium valproate, and carbamazepine, as well as newer drugs such as felbamate (derivative of carbamic acid), gabapentin and pregabalin (derivatievs of carboxylic acid), topiramate, and tiagabin.
To that group of drugs belong also derivatives of alkanolamides and alkanolamines.
Alkanolamide derivatives of cinnamic acid were described in patent application PL401500.
Patent PL211939 describes buthylmethylaminoethyltiazophenols.
Patent US41 1851 1A describes aryloxyaminobutanols.
Aminoalkanols, for example l-isopropylamino-3-(naphtyloxy)-2-propanol [J. W. Black, et al., Lancet, 1, 1080 (1964)] acting as potent β-inhibitor, or alkyl ethers of 3-amino-l-phenoxy-2- propanol showing stimulating effect on central nervous system were described in [J W. Black, et al ., Lancet, 1, 1080 (1964)].
There are also known derivatives of 1,2-aminoalkanols [H. Marona, L. Antkiewicz-Michaluk, Acta Pol. Pharm., 1998, vol. 55, nr 6, str. 487-498] and derivatives of aryloxyacetamides and aryloxyethylamines [H. Marona, A.M. Waszkielewicz, E. Szneler, Acta Pol. Pharm., 2005, vol. Vol. 62, nr 5, str. 345-353].
Patent PL212489 describes phenoxyalkylaminoalkanols. Those compounds influence the stabilization of functional membrane potential of cells possessing their own electrical function, including nervous cells, what results in possessing potential activity in nervous system disorders.
It was unexpectedly shown, especially according to very beneficial results of in vivo pharmacological tests, that incorporating ether moiety between phenoxy and alkylaminoalkanol groups of phenoxyalkylaminoalkanols significantly improved the specificity of mechanism of action of the last. The derivatives obtained according to the invention of N- [(phenoxy)ethoxy]alkylaminoalkanols similary to phenoxyalkylaminoalkanols are characterized by beneficial pharmacological properties, especially in the treatment and/or prophylaxis of disorders and symptoms with neurological etiology, such as epilepsy and pain. They possess significantly more selective binding to sigma receptors when compared to other tested receptors. Such properties correlate with safer usage of the drugs in pharmacotherapy and decreased number of adverse effects.
The main subject of the solution presented within current invention constitutes N- [(phenoxy)ethoxy]alkylaminoalkanols with general structure 1.
Figure imgf000003_0001
In which Rl is
. 2,6-(CH3)2
. 2,3-(CH3)2
. 2,4-(CH3)2
. 2,4,6-(CH3)3
. 2-Cl, 6-CH3
And R2 is aminoalkanol selected from the following: (R,S)-2-aminopropan-l-ol; (R)-2- aminopropan-l-ol; (S)-2-aminopropan-l-ol; (R, S)-2-aminobutan- 1 -ol, (R)-2-aminobutan-l-ol, (S)- 2-aminobutan-l-ol, trans-(D,L)-2-aminocyclohexanol; trans-4-aminocyclohexanol; (R,S)-2-amino- 1-phenyloethanol; 4-hydroxypiperidine, and their accepted for usage in pharmacotherapy salts and pro-drugs. Compounds selected according to present invention are presented in Table 1 below.
Table 1.
Figure imgf000004_0001
Figure imgf000005_0001
Another solution according to the invention is also the usage of N- [(phenoxy)ethoxy]alkylaminoalkanols with general structure 1, in which Rl constitutes (CH3)2, (CH3)3, or CI and CH3, and R2 constitutes aminoalkanol selected from the following: (R,S)-2- aminopropan-l-ol, (R)-2-aminopropan-l-ol, (S)-2-aminopropan-l-ol, (R, S)-2-aminobutan- 1 -ol, (R)-2-aminobutan-l-ol, (S)-2-aminobutan-l-ol, trans-(D,L)-2-aminocyclohexanol, trans-4- aminocyclohexanol, (R,S)-2-aminol-phenylethanol, 4-hydroxypiperidine, and their possible salts accepted for the usage in pharmacotherapy, for the preparation of drug used in the treatment and prophylaxis of disorders or symptoms with neurological etiology, especially epilepsy and/or pain.
Example 1. The detailed description of synthesis of intermediate products and subject compounds.
The reactions of synthesis of appropriate N-[(phenoxy)ethoxy]alkylaminoalkanols were carried out by means of N-alkylation of appropriate aminoalkanols by bromide of appropriate [(phenoxy)ethoxy]alkyl. Some compounds were characterized as hydrochlorides, and the solution of HC1 in ethanol was used for the conversion.
To obtain compounds as racemates, enantiomers or achiral structures commercially available reagents (phenols, aminoalkanols) were used, with the exception of trans-D,L-2- aminocyclohexanol, which was obtained by means of know methods.
Example 1.1. Synthesis of 2,6-dimethyl-; 2,3-dimethyl-; 2,4-dimethyl-; 2,4,6,-trimethyl-; 2- chlor-6-methyl- phenoxyethoxyethanol.
In the three-neck round-bottom flask of 750 mL there was prepared a reaction mixture containing 200 mL acetone, 0.6 mole anhydrous K2CO3, 0.5 mole 2-(2-chlorethoxy)ethanol and 0.2 mole of appropriate phenol: 2,6-dimethylphenol, 2,3-dimethylphenol, 2,4-dimethylphenol, 2,4,6- trimethylphenol, or 2-chlor-6-methylphenol. The mixture was being heated and refluxed for over a dozen hours, then the reaction mixture was filtered, and a filtrate was evaporated under reduced pressure to obtain oily residue, which was afterwards diluted with 200 mL of water and alkalified with 10% NaOH under the control of universal indicator paper. The product was extracted with toluene, the organic phase was washed with 5% NaOH, water and dried over anhydrous NaiSOzt. After evaporation of solvent the crude product was obtained, which was used in further reactions without purification.
Example 1.2. Synthesis of 2,6-dimethyl-; 2,3-dimethyl-; 2,4-dimethyl-; 2,4,6,-trimethyl-; 2- chlor-6-methyl- phenoxyethoxyethyl bromides.
In the round-bottom flask of 500 mL there were placed 0.15 mole of appropriate 2,6-dimethyl-; 2,3- dimethyl-; 2,4-dimethyl-; 2,4,6,-trimethyl-; or 2-chlor-6-methyl- [(phenoxy)ethoxy] ethanol and 0.75 mole PBr3 was added in small portions. The reagents were heated and refluxed in water bath for 1.5 hour. Then, the reagents were poured into a beaker with ice and neutralized with 15% of NaHC03, then the mixture was extracted with toluene. After drying the organic layer over anhydrous Na2S04 the solvent was evaporated, and oily residue was obtained.
Example 1.3. Synthesis of the subject compounds.
In the round-bottom flask of 250 mL there was placed 0.015 mole of appropriate 2,6-dimethyl-; 2,3- dimethyl-; 2,4-dimethyl-; 2,4,6,-trimethyl-; 2-chlor-6-methyl- [(phenoxy)ethoxy]ethyl bromide, 0.12 mole appropriate aminoalkanol, and 0.2 mole anhydrous K2CO3. The mixture was being heated and refluxed in 50 mL of toluene for about 5 hours, then the reaction mixture was left to cool down, silica gel was added, and the mixture was again brought to boil. Then the reaction mixture was filtered, and filtrate was evaporated under reduced pressure to obtain oily residue, then 50 mL of water and 10% HC1 were added to obtain acidic pH under the control of universal indicator paper and activated charcoal was added afterwards. The mixture was refluxed for a while. Then the mixture was filtered, and the filtrate was alkalified with 10% NaOH to obtain crude base, which was afterwards extracted with toluene. Organic layer was dried over anhydrous Na2S04, and the organic solvent was evaporated to obtain oily residue, from which product was crystallized by means of «-hexane. Some compounds were converted into hydrochlorides using the ethanol solution of HC1. Hydrochlorides were crystallized with acetone.
Example 2. Physicochemical data of selected compounds according to the invention
For selected compounds according to the invention, using standard analytical technics, there were found parameters such as: melting point (M.p.), elemental analysis of carbon, nitrogen, and hydrogen content, :H NMR spectrum, specific rotation [a] for enantiomers. H- 16/ 10 - R,S-2-({2- [2-(2,6-Dimethylphenoxy)ethoxy] ethyl} mino)propan- l-ol
M.p =46-48°C; Ccalc/Cf0und 67.38/67.21; Hcaic/Hfound 9.42/9.66; Ncaic/Nf0und 5.24/5.12
¾NMR (CDC13): δ ppm 7.00 (d, J=7.4; 2H, Ar-H3), 6.92 (dd, J=8.1; J=6.2; IH, Ar-H4), 3.98-3.92 (m, 2H, Ar-0-CH2), 3.84-3.78 (m, 2H, A1--O-CH2-CH2), 3.74-3.67 (m, 2H, 0-CH2-CH2-NH), 3.61 (dd, J=10.5; J=3.7; IH, CHH-OH), 3.30 (dd, J=11.2; J=7.2; IH, CHH-OH), 3.06-2.96 (m, IH, O- CH2-CHH-NH), 2.91-2.74 (m, IH, 0-CH2-CHH-NH), 2.91-2.74 (m, IH, NH-CH), 2.41 (bs, 2H, OH, NH), 2 29 (s, 6H, Ar-CH3), 1.09 (d, J=6 7; 3H, CH-CH3)
H-21/10 - R(-)-2-({2-[2-(2,6-Dimethylphenoxy)ethoxy]ethyl}amino)propan-l-ol
M.p =46-48°C; CCaic/Cf0und 67.38/67.31; Hcalc/Hfound 9.42/9.70; Ncaic/Nf0und 5.24/5.04
¾ NMR (CDCI3): δ ppm 7.00 (d, J=7.4; 2H, Ar-H3), 6.92 (dd, J=8.1; J=6.2; IH, Ar-H4), 3.98-3.92 (m, 2H, Ar-0-CH2), 3.84-3.78 (m, 2H, A1--O-CH2-CH2), 3.74-3.67 (m, 2H, 0-CH2-CH2-NH), 3.61 (dd, J=10.5; J=3.7; IH, CHH-OH), 3.30 (dd, J=11.2; J=7.2; IH, CHH-OH), 3.06-2.96 (m, IH, O- CH2-CHH-NH), 2.91-2.74 (m, IH, 0-CH2-CHH-NH), 2.91-2.74 (m, IH, NH-CH), 2.41 (bs, 2H, OH, NH), 2.29 (s, 6H, Ar-CH3), 1.09 (d, J=6.7; 3H, CH-CH3). [aD 20]= -13.250.
H-50/09 - R(-)-2-({2-[2-(2,6-Dimethylphenoxy)ethoxy]ethyl}amino)propan-l-ol hydrochloride
M.p =98-100°C; Ccaic/Cfound 59.29/58.98; Hcalc/Hfound 8.63/8.68; Ncaic/Nfound 4.53/4.59
¾ NMR (DMSO-d6): δ ppm 8.50 (bs, 2H, NH2 +), 7.01-6.99 (m, 2H, Ar-H), 6.92-6.87 (m, IH, Ar- H), 5.36 (t, J=5.1; IH, OH); 3.89-3.86 (m, 2H, Ar-0-CH2), 3.79-3.74 (m, 4H, Ar-0-CH2-CH2-0- CH2-CH2-NH), 3.64-3.58 (m, IH, CHH-OH), 3.52-3.44 (m, IH, CHH-OH), 3.32-3.23 (m, IH, NH- CH), 3.14 (t, 2H, J=5.6; 0-CH2-CH2-NH), 2.20 (s, 6H, Ar-CH3), 1.70 (d, J=6.7; 3H, CH-CH3).
H-19/10 - S(+)-2-({2-[2-(2,6-Dimethylphenoxy)ethoxy]ethyl}amino)propan-l-ol
M.p =46-48°C; Ccalc/Cfound 67.38/67.23; Hcaic/Hfound 9.42/9.75; Ncaic/Nfound 5.24/4.99
¾ NMR (CDCI3): δ ppm 7.00 (d, J=7.4; 2H, Ar-H3), 6.92 (dd, J=8.1; J=6.2; IH, Ar-H4), 3.98-3.92 (m, 2H, Ar-0-CH2), 3.84-3.78 (m, 2H, Ar-0-CH2-CH2), 3.74-3.67 (m, 2H, 0-CH2-CH2-NH), 3.61 (dd, J=10.5; J=3.7; IH, CHH-OH), 3.30 (dd, J=11.2; J=7.2; IH, CHH-OH), 3 06-2.96 (m, IH, O- CH2-CHH-NH), 2.91-2.74 (m, IH, 0-CH2-CHH-NH), 2.91-2.74 (m, IH, NH-CH), 2.41 (bs, 2H, OH, NH), 2.29 (s, 6H, Ar-CH3), 1.09 (d, J=6.7; 3H, CH-CHj). [aD 20]=13.067.
H-23/10 - S(+)-2-({2-[2-(2,6-Dimethylphenoxy)ethoxy]ethyl}amino)propan-l-ol hydrochloride
M.p =97-99°C; Ccalc/Cfound 59.29/59.34; Hcaic/Hfound 8.63/8.80; Ncaic/Nfound 4.53/4.60
XH NMR (DMSO-de): δ ppm 8.77 (bs, IH, NHH+), 8.54 (bs, IH, NHH ), 7.00 (d, J=7.4; IH, Ar- H3), 6.89 (dd, J=8.5; J=6.5; IH, Ar-H4), 5.37 (t, J=5.3; IH, OH); 3.90-3.87 (m, 2H, Ar-0-CH2), 3.81-3.74 (m, 4H, Ar-0-CH2-CH2-0-CH2-CH2-NH), 3.63 (dt, J=11.8; J=4.3; IH, 0-CH2-CHH- NH), 3.50 (dt, J=11.8; J=5.4; 0-CH2-CHH-NH), 3.28 (bs, IH, NH-CH), 3.15 (bs, 2H, CH2-OH), 2.21 (s, 6H, A1--CH3), 1.19 (d, J=6.7; 3H, CH-CH3).
H-22/10 - R,S-2-({2-[2-(2,6-Dimethylphenoxy)ethoxy]etylo}amino)butan-l-ol
M.p =48-50°C; Ccalc/Cfound 68.29/68.40; Hcaic/Hfound 9.67/10.07; Ncaic/Nf0und 4.98/4.88
¾ NMR (CDCI3): δ ppm 7.00 (d, J=7.6; 2H, Ar-H3), 6.92 (dd, J=8.6; J=6.5; IH, Ar-H4), 3.96-3.92 (m, 2H, Ar-0-CH2), 3.86-3.81 (m, 2H, Ar-0-CH2-CH2), 3.76 (t, J=4.9; 2H, 0-CH2-CH2-NH), 3.71 (dd, J=11.4; J=4.0; IH, CHH-OH), 3.43 (dd, J=l l. l; J=6.5; IH, CHH-OH), 3.05 (dt, J=12.0; J=5.5; IH, 0-CH2-CHH-NH), 2.90 (dt, J=12.9; J=4.6; IH, 0-CH2-CHH-NH), 2.76-2.66 (m, IH, NH-CH), 2.58 (bs, 2H, OH, NH), 2.29 (s, 6H, Ar-CH3), 1.64-1.45 (m, 2H, CH-CH2-CH3), 0.95 (t, J=7.7; 3H, CH-CH2-CH3) H-61/10 - R(-)-2-({2-[2-(2,6-Dimethylphenoxy)ethoxy]ethyl}amino)butan-l-ol
M.p =50-52°C; Ccalc/Cfound 68.29/68.14; Hcaic/Hfound 9.67/9.66; Ncaic/Nf0und 4.98/4.91
XH NMR (CDC13): δ ppm 7.05-6.97 (m, 2H, Ar-H3), 6.96-6.87 (m, IH, Ar-H4), 3.97-3.91 (m, 2H, A1--O-CH2), 3.83-3.77 (m, 2H, Ar-0-CH2-CH2j, 3.72-3.64 (m, 2H, O-CH2-CH2-NH), 3.61 (dd, J=10.6; J=4.0; IH, CHH-OH), 3.29 (dd, J=10.8; J=6.4; IH, CHH-OH), 2.99-2.88 (m, IH, 0-CH2- CHH-NH), 2.81-2.71 (m, IH, 0-CH2-CHH-NH), 2.62-2.51 (m, IH, NH-CH), 2.29 (s, 6H, Ar-C¾), 1.56-1.36 (m, 2H, CH-CH2-CH3), 0.92 (t, J=7.4; 3H, CH-CH2-CH2) [aD 20]= -11.719.
H-32/10 - S(+)-2-({2-[2-(2,6-Dimethylphenoxy)ethoksy]ethyl}amino)butan-l-ol
M.p =51-53°C; CCaic/Cf0und 68.29/67.83; Hcalc/Hfound 9.67/9.78; Ncaic/Nf0und 4.98/4.91
¾ NMR (CDCI3): δ ppm 7.00 (d, J=7.6; 2H, Ar-H3), 6.92 (dd, J=8.6; J=6.5; IH, Ar-H4), 3.96-3.92 (m, 2H, Ar-0-CH2), 3.86-3.81 (m, 2H, Ar-O-CHj-Cfb), 3.72 (t, J=4.9; 2H, 0-CH2-CH2-NH), 3.67 (dd, J=11.4; J=4.0; IH, CHH-OH), 3.37 (dd, J=1 1.2; J=6.7; IH, CHH-OH), 3.00 (m, IH, 0-CH2- CHH-NH), 2.90 (dt, 7=12.5; 7=4.5; IH, 0-CH2-CHH-NH), 2.76-2.66 (m, IH, NH-CH), 2.58 (bs, 2H, OH, NH), 2.29 (s, 6H, Ar-CH3), 1.64-1.45 (m, 2H, CH-CH2-CH3), 0.95 (t, 7=8.2; 3H, CH-CH2-
Figure imgf000008_0001
H-58/10 - trans-(D,L)-2-({2-[2-(2,6-Dimethylphenoxy)ethoxy]ethyl}amino)cyclohexanol
M.p =47-49°C; Ccalc/Cfound 70.32/70.98; Hcaic/Hfound 9.51/9.53; Ncaic/Nfound 4.56/4.51
XH NMR (CDCI3): 7.01-6.89 (m, 3H, Ar-H), 3.95-3.92 (m, 2H, Ar-0-CH2), 3.81-3.79 (m, 2H, Ar- O-CH2-CH2), 3.69-3.66 (m, 2H, CH2-CH2-NH), 3.18-3.12 (m, IH, CH-OH), 3.12-3.03 (m, IH, CHH-NH), 2.72-2.65 (m, IH, 0-CH2-CHH-NH), 2.29 (s, 6H, Ar-CH3), 2.27-2.19 (m, IH, NH), 2.11-2.02 (m, 2H, cyclohex.), 1.74-1.69 (m, 2H, cyclohex), 1.24-1.29 (m, 4H, cyclohex).
H-66/10 - (R,S)-2-({2-[2-(2,6-Dimethylphenoxy)ethoxy]ethyl}amino)-l-phenylethanol
M.p =110-112°C; Ccaic/Cfoiind 72.92/72.52; Hcaic/Hfound 8.26/8.07; Ncaic/Nfoiind 4.25/4.21.
XH NMR (CDCI3): δ ppm 7.40-7.25 (m, 5H, Ar-H), 7.03-6.89 (m, 3H, Ar-H), 4.70 (dd, 7=9.2; 7=3.6; IH, Ar-CH-OH), 3.97-3.92 (m, 2H, Ar-0-CH2), 3 82-3.78 (m, 2H, Ar-O-CHz-CTb), 3.86 (t, 7=4.9; 2H, CH2-CH2-NH), 2.98-2.87 (m, 3H, NH-CHH-CH-Ar + CH2-CH NH), 2.72 (dd, 7=12.3; 7=9.2; IH, NH-CHH-CH-Ar), 2.28 (s, 6H, Ar-CH3).
H- 101/10 - l-{2-[2-(2,6-Dimethylphenoxy)ethoxy]ethyl}-4-hydroxypiperidyne
M.p =51-53°C; Ccalc/Cfound 69.59/69.41; Hcaic/Hfound 9.28/9.23; Ncaic/Nfound 4.77/4.75
XH NMR (CDCI3): δ ppm 7.02-6.97 (m, 2H, Ar-H3), 6.94-6.88 (m, IH, Ar-H4), 3.96-3.89 (m, 2H, Ar-0-CH2), 3.81-3.76 (m, 2H, Ar-O-CHz-CHj), 3.70 (t, 7=5.7; CHH-CH2-NH), 3.72-3.68 (m, IH, CH-OH), 2.91-2.79 (m, 2H, N-CH2(pip)), 2.64 (t, 2H, 7=5.7; CH2-CH2-NH), 2.28 (s, 6H, Ar-CH3), 2.27-2.17 (m, 2H, N-CH2(pip)), 1.96-1.84 (m, 2H, CH2(pip)), 1.69-1.53 (m, 2H, CH2(pip)).
H-l 11/10 - R,S-2-({2-[2-(2-Chloro-6-methylphenoxy)ethoxy] ethyl} amino)butan-l-ol
M.p =34-36°C; Ccalc/Cfound 59.69/59.61; Hcaic/Hfound 8.02/8.21; Ncaic/Nfound 4.64/4.57
XH NMR (CDC13): δ ppm 7.22-6.90 (m, 3H, Ar-H), 4.14-4.08 (m, 2H, Ar-0-CH2), 3.86-3.80 (m, 2H, Ar-0-CH2-CH2), 3.70-3.58 (m, 3H, CH2-CH2-NH + CHH-OH), 3.35-3.25 (m, IH, CHH-OH), 2.98-2.88 (m, IH, CH2-CHH-NH), 2.80-2.70 (m, IH, CH2-CHH-NH), 2.60-2.52 (m, IH, NH-CH), 2.33 (s, 3H, Ar-CH3), 1.55-1.35 (m, 2H, CH CH3), 0.90 (t, 7=7.4; 3H, CH2-CH3).
H-86/10 - R(-)-2-({2-[2-(2-Chloro-6-methylphenoxy)ethoxy]ethyl}amino)butan-l-ol
M.p =40-42°C; Ccal7Cfound 59.69/59.57; Hcaic/Hfound 8.02/8.08; Ncaic/Nfound 4.64/4.59 XH NMR (CDCI3): δ ppm 7.20 (d, J=7.9; IH, Ar-H), 7.07 (d, J=7.9; IH, Ar-H), 6.94 (t, J=7.9; IH, Ar-H4), 4.10 (t, J=4.6; 2H, Ar-0-CH2), 3.88-3.80 (m, 2H, Ar-0-CH2-CH2), 3.70-3.65 (m, 2H, CH2- CH2-NH), 3.60 (dd, 7=12.0; 7=4.1; IH, CHH-OH), 3.30 (dd, 7=10.5; 7=6.4; IH, CHH-OH), 2.98- 2.88 (m, IH, CH2-CHH-NH), 2.80-2.72 (m, IH, CH2-CHH-NH), 2.60-2.52 (m, IH, NH-CH), 2.33 (s, 3H, Ar-CH3), 1.58-1.35 (m, 2H, CH2-CH3), 0.92 (t, 7=7.4; 3H, CH2-CH3). [aD 20]= -5.728.
H-33/10 - S-(+)-2-({2-[2-(2-Chloro-6-methylphenoxy)ethoxy]ethyl}amino)butan-l-ol
M.p =40-42°C; Ccalc/Cfound 59.69/59.34; Hcaic/Hfound 8.02/8.21; Ncaic/Nfound 4.64/4.47
XH NMR (CDCI3): δ ppm 7.20 (d, 7=8.2; IH, Ar-H), 7.07 (d, 7=7.5; IH, Ar-H), 6.95 (t, 7=7.5; IH, Ar-H4), 4.13-4.07 (m, 2H, Ar-0-CH2), 3.89-3.84 (m, 2H, Ar-0-CH2-CH2), 3.78 (t, 7=5.2; 2H, CH2- CH2-NH), 3.72 (dd, 7=11.3; 7=3.7; IH, CHH-OH), 3.45 (dd, 7=11.3; 7=6.1; IH, CHH-OH), 3.06 (dt, 7=12.5; 7=5.7; IH, CH2-CHH-NH), 2.92 (dd, 7=12.5; 7=4.7; IH, CH2-CHH-NH), 2.78-2.69 (m, IH, NH-CH), 2.54 (bs, 2H, NH, OH), 2.33 (s, 3H, Ar-CH3), 1.58-1.35 (m, 2H, CH2-CH3), 0.92 (t, 7=7.4; 3H, CH2-CH3).
H-78/ 10 - R,S-2-({2- [2-(2-Chloro-6-methylphenoxy)ethoxy] ethyl}amino)-4-hydroxypiperidine
M.p =52-54°C, CCai7Cfound 61.24/61.25; Hcalc/Hfound 7.71/7.68; Ncaic Nf0und 4.46/4.43
XH NMR (CDCI3): δ ppm 7.22-6.82 (m, 3H, Ar-H), 4.08 (t, 7=4.6; 2H, Ar-0-CH2), 3.82 (t, 7=4.6; 2H, Ar-0-CH2-CH2), 3.75 (t, 7=5.8; 2H, 0-CH CH2-N + bs, IH, CH-OH), 2.90-2.86 (m, 2H, pip ), 2.69 (t, 7=5.8; 2H, 0-CH2-CH N), 2.34-2.32 (m, 2H, pip.), 2.32 (s, 3H, Ar-CH3), 1.98-1.93 (m, 2H, pip ), 1.72-1.61 (m, 2H, pip ).
H-79/10 - R,S-2-({2-[2-(2-Chloro-6-methylphenoxy)ethoxy]ethyl}amino)-l-phenylethanol
T=100-102°C; Ccaic/Cf0und 65.23/65.06; Hcalc/Hf0Und 6.91/6.83; Ncaic/Nf0und 4.00/4.00
'H NMR (DMSO-d6): δ ppm 7.35-7.32 (m, 2H, Ar-H), 7.31-7.29 (m, 2H, Ar-H), 7.28-7.26 (m, IH, Ar-H), 7.23-7.19 (m, IH, Ar-H), 7.19-7.16 (m, IH, Ar-H), 7.03 (dd, 7=7.8; 7=7.6; IH, Ar-H), 5.23 (d, 7 =4.4, IH, OH), 4.62-4.58 (m, IH, Ar-CH-OH ), 4.00 (t, 7=4.8; 2H, Ar-0-CH2), 3.70 (t, 7=4.8; 2H, Ar-0-CH2-CH2), 3 53 (t, 7=5 5; 2H, CH CH2-NH), 2.71 (t, 7=5.5; 2H, CH NH), 2.68-2.61 (m, IH, NH-CHH-CH-Ar), 2.26 (s, 3H, Ar-CH3), 1.78 (bs, 2H, NH).
H-59/ 10 - R,S-2-({2- [2-(2,4,6-Trimethylphenoxy)ethoxy] ethyl} amino)propan- l-ol
M.p =53-55°C; Ccalc/Cfound 68.29/68.29; Hcaic/Hfound 9.67/9.61; Ncaic/Nfound 4.98/4.86
^ NMR CDCls): δ ppm 6.81 (s, 2H, Ar-H), 3.97-3.86 (m, 2H, Ar-0-CH2), 3.83-3.75 (m, 2H, Ar- O-CH2-CH2), 3.72-3.63 (m, 2H, O-CH -CH2-NH), 3.58 (dd, 7=10.5; 7=4.1; IH, CHH-OH), 3.25 (dd, 7=10.6; 7=6.8; IH, CHH-OH), 3.05-2.89 (m, IH, 0-CH2-CHH-NH), 2.86-2.68 (m, 2H, 0-CH2- CHH-NH + CH-CH2-OH), 2.25 (s, 6H, Ar-CH3), 2.23 (s, 3H, Ar-CH3), 1.05 (d, 7=6.7; 3H, CH- CH3).
H-l 16/10 - trans-D,L-2-({2-[2-(2,4,6-Trimethylphenoxy)ethoxy]ethyl}amino)cyclohexanol
M.p =54-56°C; Ccalc/Cfound 70.93/70.90; Hcaic/Hfound 9.72/9.53; Ncaic/Nfound 4.36/4.35
¾ NMR (CDC13): 6.81 (s, 2H, Ar-H), 3.94-3.87 (m, 2H, Ar-0-CH2), 3.81-3.75 (m, 2H, Ar-0-CH2- CH2), 3.70-3.62 (m, 2H, O-CH2-CH2-NH), 3.44 (bs, IH, NH), 3.23-3 11 (m, IH, CH-OH), 3.11- 3.00 (m, IH, O-CH2-CHH-NH), 2.67 (dt, 7=12.2; 7=4.6; IH, 0-CH2-CHH-NH), 2.25 (s, 6H, Ar- CH3), 2.23 (s, 3H, Ar-CH3), 2.22-2.16 (m, IH, CH-NH), 2.12-1.98 (m, 2H, cyclohex ), 1.77-1.66 (m, 2H, cyclohex.), 1.35-1.17 (m, 3H, cyclohex.), 1.06-0 91 (m, IH, cyclohex.)
H-30/11 - R,S-2-({2-[2-(2,3-Dimethylphenoxy)ethoxy]ethyl}amino)propan-l-ol
M.p =50-52°C; Ccalc/Cfound 67.38/67.42; Hcalc/Hfound 9.42/9.36; Ncaic/Nfound 5.24/5.11 XH NMR (CDCI3): δ ppm 7.04 (t, J=7.7; 1H, Ar-H5), 6.78 (d, J=7.4; 1H, Ar-H4), 6.72 (d, 7=8.2, 1H, Ar-H6), 4.11 (d, J=4.6; 2H, Ar-0-CH2), 3.87-3.82 (m, 2H, Ar-0-CH2-CH2), 3.72-3.65 (m, 2H, O-CH2-CH2-NH), 3.58 (dd, J=10.5; J=4.1; 1H, CHH-OH), 3.22 (dd, J=10.5; J=6.7; 1H, CHH-OH), 2.99-2.90 (m, 1H, 0-CH2-CHH-NH), 2.82-2.68 (m, 2H, 0-CH2-CHH-NH + NH-CH), 2.27 (s, 3H, A1--CH3), 2.16 (s, 3H, Ar-C¾), 1.05 (d, J=6.7; 3H, CH-CH3).
H-52/12 - trans-D,L-2-({2-[2-(2,3-Dimethylphenoxy)ethoxy]ethyl}amino)cyclohexanol
M.p =84-85°C; Ccaic/Cfound 70.32/69.94; Hcaic/Hfound 9.51/9.79; Ncaic Nfound 4.56/4.55
XH NMR (CDCI3): δ ppm 7.03 (t, 7=7.8; 1H, Ar-H5), 6.78 (d, 7=7.4; 1H, Ar-H4), 6.71 (d, 7=8 2, 1H, Ar-H6), 4.12-4.09 (m, 2H, Ar-0-CH2), 3.85-3.81 (m, 2H, Ar-O-CTt-CEb), 3.69-3.65 (m, 2H, 0-CH2-CH2-NH), 3.40 (bs, 1H, OH), 3.18- 3.10 (m, 1H, CH-OH), 3.07-2.99 (m, 1H, 0-CH2-CHH- NH), 2.68-2.61 (m, 1H, 0-CH2-CHH-NH), 2.67 (s, 3H, Ar-CH3), 2.23-2.17 (m, 1H, CH-NH), 2.16 (s, 3H, A1--CH3), 2.08-2.00 (m, 2H, cyclohex.), 1.72-1.69 (m, 2H, cyclohex.), 1.34-1.18 (m, 3H, cyclohex.), 1.02-0.94 (m, 1H, cyclohex.)
H-78/12 - trans-4-({2-[2-(2,3-Dimethylphenoxy)ethoxy]ethyl}amino)cyclohexanol
M.p =68-70°C; Ccalc/Cfound 70.32/70.69; Hcaic/Hfound 9.50/9.12; Ncaic/Nfound 4.56/4.33
XH NMR (DMSO-d6): δ ppm 7.07 (dd, J=8.1; J=7.5; 1H, Ar-H5), 6.78 (d, J=8.1; 1H, Ar-H6), 6.75 (d, J=7.5; 1H, Ar-H4), 4.43 (bs, 1H, -OH), 4.04 (ddd, J=6.2; 7=4.7; J=3.2; 2H, Ar-0-CH2), 3.71 (ddd, J=6.2; J=4.7; J=3.2; 2H, Ar-0-CH2-CH2), 3.51 (t, J=5.7; 2H, 0-CH CH2-NH), 3.36- 3.30 (m, 1H, CH-OH), 2.66 (t, J=5.7; 2H, 0-CH2-CH2-NH), 2.29 (tt, J=10.6; J=3.5; 1H, CH-NH), 2.20 (s, 3H, A1--CH3), 2.07 (s, 3H, Ar-CH3), 1.80-1.73 (m, 4H, cyclohex.), 1.40 (bs, 1H, -NH), 1.16-1.07 (m, 2H, cyclohex.), 1.01-0.92 (m, 2H, cyclohex.).
H-79/12 - l-{2-[2-(2,3-Dimethylphenoxy)ethoxy]ethyl}-4-hydroxypiperidine hydrochloride
M.p =138-140°C; Ccaic Cf0llnd 61.90/61.58; Hcaic/Hfoimd 8.55/8.29; Ncaic/Nf0llnd 4.25/4.21
XH NMR (DMSO-de): δ ppm 10.67 (bs, 1H, NH+), 7.00 (dd, J=8.2; J=7.4; 1H, Ar-H5), 6.78 (d, J=8.2; 1H, Ar-H6), 6.75 (d, J=7.4; 1H, Ar-H4), 4.79 (bs, 1H, OH); 4.10 (ddd, J=6.1; J=4.7; J=3.3 ; 2H, Ar-0-CH2), 3.91 (t, J=5.2; 2H, 0-CH2-CH2-NH), 3.88 (bs, 1H, CH-OH), 3.80 (ddd, 7=6.1; 7=4.7; 7=3.3; 2H, Ar-0-CH2-CH2-), 3.65 (bs, 2H, N-CH2(pip)), 3.41 (bs, 2H, N-CH2(pip)), 1.98 (bs, 2H, CH2(pip)), 1.74 (bs, 2H, CH2(pip)), 3.22 (t, 7=5.2; 2H, 0-CH2-CH2-NH), 2.21 (s, 3H, Ar-CH3),
Figure imgf000010_0001
H-89/12 - R,S-2-({2-[2-(2,4-Dimethylphenoxy)ethoxy]ethyl}amino)propan-l-ol
M.p =46-48°C; Ccalc/Cf0Und 67.38/66.92; Hcaic/Hfound 9.42/9.42; Ncaic/Nf0Und 5.24/5.05
XH NMR (CDCI3): δ ppm 6.95-6.71 (m, 3H, Ar-H), 4.12-4.08 (m, 2H, Ar-0-CH2), 3.85-3.80 (m,
2H, Ar-0-CH2-CH2), 3.70-3.65 (m, 2H, 0-CH2-CH2-NH), 3.58 (dd, 7=10.5; 7=4.1; 1H, CHH-OH),
3.25 (dd, 7=10.6; 7=6.9; 1H, CHH-OH), 3.00-2.90 (m, 1H, 0-CH2-CHH-NH), 2.85-2.68 (m, 2H, O-
CH2-CHH-NH + CH-CH2-OH), 2.25 (s, 3H, Ar-CH3), 2.20 (s, 3H, Ar-CH3), 1.05 (d, 7=6.4; 3H,
CH-CH3).
Evaluation of pharmacological activity of compounds according to the invention was performed at National Institutes of Health in Rockville, USA within Antiepileptic Drug Development (ADD) Program. Pharmacological tests were performed according to published procedures, which previously served for identification of biological activity of currently used antiepileptic and/or analgesic drugs. The research were conducted to provoke in tested animals some states corresponding with clinical symptoms observed in humans in the course of neurological disorders such as epilepsy or pain. For example, maximal electroshock (MES) test described below conducted in rodents corresponds with tonic-clonic seizures in epilepsy in humans. Activity in the chemical test of subcutaneous pentetrazole (scMet) forecasts the activity of the compound in absence seizures in humans. 6-Hz test belongs to the animal models of resistant seizures, and activity shown in that test is considered as good predictor for efficacy in psychomotor and focal seizures in humans. The activity on 6-Hz test means moreover possible activity in inhibition of so called epileptogenesis, which is development of epilepsy as a disorder. Activity in pilocarpine test corresponds with prevention of status epilepticus. Activity in formalin test corresponds with inhibition of pain with neurogenic etiology (first phase) and/or pain with inflammatory etiology (second phase) [Bialer, M; White, H. S. Key factors in the discovery and development of new antiepileptic drugs. Nature Rev Drug Discov. 2010,9, 68-82; Loscher, W. Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure 201 1, 20, 359-368].
Screening tests
In the subject invention the first phase of evaluation of activity constituted screening in MES and scMet tests. Additionally evaluation of neurotoxicity was conducted in order to establish possible adverse effects from nervous system caused by tested substances. The tests were performed in Carworth Farms 1 mice (intraperitoneal administration, i.p.) and Spague-Dawley rats (oral administration, p.o. and intraperitoneal administration, i.p)
[http://www.ninds.nih.gov/research/asp/testdesc.htm; White, H. S.; Woodhead, J. H.; Wilcox, K. S.; Stables, J. P.; Kupferberg, H. J.; Wolf, H. H. D. Discovery and preclinical development of antiepileptic drugs. W: Antiepileptic Drugs Fifih Edition; Levy, R. H.; Mattson, R. H.; Mel drum, B. S.; Perucca, E., Eds.; Lippincott Williams & Wilkins: Philadelphia, 2002; p. 36-48].
Neurotoxicity evaluation
In mice the test of rotating rod (rotorod test) was performed. In the test the knurled plastic rod rotating 6 times per minute was used. In normal conditions mice are able to remain on rod for long time. If the animal is not able to remain on the rod in every of 3 trials of 1 minute duration it is assumed that the substance caused neurotoxicity.
In rats the neurotoxicity was scored according to observations of the behaviour. As symptoms of neurotoxicity there are considered among others impaired movement ability ('zig-zag', circle), ataxia, abnormal placement of limb and abnormal posture, tremors, hyperactivity, somnolence, stupor, loss of cognitive activity, catalepsy [http://www.ninds.nih.gov/research/asp/testdesc.htm; White, H. S.; Woodhead, J. H.; Wilcox, K. S.; Stables, J. P.; Kupferberg, H. J.; Wolf, H. H. D. Discovery and preclinical development of antiepileptic drugs. W: Antiepileptic Drugs Fifih Edition; Levy, R. H.; Mattson, R. H.; Meldrum, B. S.; Perucca, E., Eds.; Lippincott Williams & Wilkins: Philadelphia, 2002; p. 36-48].
Maximal electroshock test (MES)
In the MES test for provoking the seizures electric current was used at 60 Hz and 50 mA (in mice) or 150 mA (in rats) and delivered for 0.2 s via corneal electrodes. The compound is classified as active when it protects from occurring of characteristic hindlimb extension. It is generally accepted that MES test enables verification of anticonvulsant activity in tonic-clonic generalized seizures [http://www.ninds.nih.gov/research/asp/testdesc.htm; White, H. S.; Woodhead, J. H.; Wilcox, K. S.; Stables, J. P.; Kupferberg, H. J.; Wolf, H. H. D. Discovery and preclinical development of antiepileptic drugs. W: Antiepileptic Drugs Fifth Edition; Levy, R. H.; Mattson, R. H.; Mel drum, B. S.; Perucca, E., Eds.; Lippincott Williams & Wilkins: Philadelphia, 2002; p. 36-48].
Pentetrazole test (scMet)
In the test for provoking the seizures subcutaneously administered pentetrazole was used at the dose of 85 mg/kg (mice) or 70 mg/kg (rats). The tested animal is placed in separate cage and observed for 30 min. The activity of the compound is scored according to absence of occurring of even a single episode of seizures [http://www.ninds.nih.gov/research/asp/testdesc.htm; White, H. S.; Woodhead, J. H.; Wilcox, K. S.; Stables, J. P.; Kupferberg, H. J.; Wolf, H. H. D. Discovery and preclinical development of antiepileptic drugs. W: Antiepileptic Drugs Fifth Edition; Levy, R. H.; Mattson, R. H.; Meldrum, B. S.; Perucca, E., Eds.; Lippincott Williams & Wilkins: Philadelphia, 2002; p. 36-48].
6-Hz test
6-Hz test is conducted in mice. For the provoking the seizures electric current at frequency of 6 Hz and 22, 32, or 44 mA delivered for 3 s via corneal electrodes is used. Protection is defined as remaining the normal activity for 10 s after stimulation [http://www.ninds.nih.gov/research/asp/testdesc.htm; White, H. S.; Woodhead, J. H.; Wilcox, K. S.; Stables, J. P.; Kupferberg, H. J.; Wolf, H. H. D. Discovery and preclinical development of antiepileptic drugs. W: Antiepileptic Drugs Fifth Edition; Levy, R. H.; Mattson, R. H.; Meldrum, B. S.; Perucca, E , Eds.; Lippincott Williams & Wilkins: Philadelphia, 2002; p. 36-48],
Formalin test
Formalin test is conducted in mice. The test covers the administration of formalin to hindlimb of the animal, what causes the licking of the place of administration. The total time of licking is considered as corresponding to the intensity of pain sensation experienced by the animal. It is characteristic, that there are two phases of the test. The first phase (acute) is about 10 minutes long and corresponds to the direct stimulation of peripheral sensor and pain neurons The second phase (inflammatory) develops as the response of liberation of inflammatory mediators from impaired tissues and nerves' endings. The activity in that phase corresponds with beneficial effect in neuropathic pain. Simultaneously control tests are performed which involve administration to other animals solvent alone (e.g. methylcellulose). The shortening of the time of hindlimb licking is scored as analgesic activity [http://www.ninds.nih.gov/research/asp/testdesc.htm; White, H. S.; Woodhead, J. H.; Wilcox, K. S.; Stables, J. P.; Kupferberg, H. J.; Wolf, H. H. D. Discovery and preclinical development of antiepileptic drugs. W: Antiepileptic Drugs Fifth Edition; Levy, R. H.; Mattson, R. H.; Meldrum, B. S.; Perucca, E., Eds.; Lippincott Williams & Wilkins: Philadelphia, 2002; p. 36-48; Capone, F ; Aloisi, A. M. Refinement of pain evaluation techniques. The formalin test. Annali dell'Istituto Superiore di Sanitd 2004, 40, 223-229] .
The results of performed testes are presented in tables below.
Results of activity in MES and scMet tests and neurotoxicity evaluation conducted in mice after intraperitoneal administration of the tested compounds. Table 2.
Figure imgf000013_0001
Figure imgf000014_0001
)Number of animals protected/numer of animals tested in MES or scMet displaying signs of neurotoxicity/numer of animals tested in rotarod test;„-"- the compound was not tested incertain conditions; the number in parentheses indicates the number of observed deaths
Results of activity in MES and scMet tests as well as in neurotoxicity assessment in rats after oral administration of tested compounds
Table 3.
Compound's Dose Activity3'
Test
symbol [mg/kg] 0.25 h 0.5 h l .O h 2.0 h 4.0 h
MES 30 0/4 0/4 0/4 0/4 0/4
H-19/10
TOX 30 0/4 0/4 0/4 0/4 0/4
MES 30 0/4 0/4 0/4 0/4 0/4
H-23/10
TOX 30 0/4 0/4 0/4 0/4 0/4
MES 30 0/4 0/4 1/4 0/4 0/4
H-58/10
TOX 30 0/4 0/4 0/4 0/4 0/4
MES 30 0/4 0/4 0/4 0/4 0/4
H-32/10
TOX 30 0/4 0/4 0/4 0/4 0/4
MES 30 0/4 0/4 1/4 0/4 0/4
H-86/10
TOX 30 0/4 0/4 0/4 0/4 0/4
Screening tests in rats after intraperitoneal administration Table 4.
Compound' s Dose Activity3'
Test
symbol [mg/kg] 0.25 h 0.5 h l .O h 2.0 h 4.0 h
MES 30 4/4 4/4 3/4 0/4 0/4
H-19/10
TOX 30 0/4 0/4 0/4 0/4 0/4
MES 30 4/4 4/4 3/4 0/4 0/4
H-23/10
TOX 30 0/4 0/4 0/4 0/4 0/4 Results of quantitative evaluation
Table 5.
The ED50 and TD50 values obtained in tests in mice after intraperitoneal administration of tested compounds
Figure imgf000015_0001
Results of screening in 6-Hz test after intraperitoneal administration of the tested compounds
Table 6.
Figure imgf000015_0002
Results of formalin test for compound H-50/09
Table 7
Dose Area Under Curve (AUC)
Test phase
[mg/kg] Control H-50/09 % of Control S E.M P Value
13.0 Acute 237.47 130.39 54.9 11.52 < 0,05
13.0 Inf amatory 819.6 665.07 81.14 10.43 > 0,05

Claims

1 Claims
1. New derivatives of N-[(phenoxy)ethoxy]alkylaminoalkanols with general structure 1.
Figure imgf000016_0001
where Rl means (CH3)2; (CH3)3 or CI and CH3
and R2 means aminoalkanol selected from the following: (R,S)-2-aminopropan-l-ol ; (R)-2- aminopropan-l-ol; (S)-2-aminopropan-l-ol; (R,S)-2-aminobutan-l-ol; (R)-2-aminobutan-l-ol; (S)- 2-aminobutan-l-ol; trans-(D,L)-2-aminocyclohexanol; trans-4-aminocyclohexanol; (R,S)-2-amino- 1 -phenyl oethanol; 4-hydroxypiperidine, and their accepted for usage in pharmacotherapy salts and pro-drugs.
2. The compound according to claim 1 characterized by that it is chosen from the group of:
R,S-2-({2-[2-(2,6-dimethylphenoxy)ethoxy]ethyl}amino)propan-l-ol
R(-)-2-({2-[2-(2,6-dimethylphenoxy)ethoxy]ethyl}amino)propan-l-ol
R(-)-2-({2-[2-(2,6-dimethylphenoxy)ethoxy]ethyl}amino)propan-l-ol hydrochloride
S(+)-2-({2-[2-(2,6-dimethylphenoxy)ethoxy]ethyl}amino)propan-l-ol
S(+)-2-({2-[2-(2,6-dimethylphenoxy)ethoxy]ethyl}amino)propan-l-ol hydrochloride
R,S-2-({2-[2-(2,6-dimethylphenoxy)ethoxy]etylo}amino)butan-l-ol
R(-)-2-({2-[2-(2,6-dimethylphenoxy)ethoxy]ethyl }amino)butan- 1 -ol
S(+)-2-({2-[2-(2,6-dimethylphenoxy)ethoksy]ethyl}amino)butan-l-ol
trans-(D,L)-2-({2-[2-(2,6-dimethylphenoxy)ethoxy]ethyl}amino)cyclohexanol
(R,S)-2-({2-[2-(2,6-dimethylphenoxy)ethoxy]ethyl}amino)-l-phenylethanol
l-{2-[2-(2,6-dimethylphenoxy)ethoxy]ethyl}-4-hydroxypiperidyne
R,S-2-({2-[2-(2-chloro-6-methylphenoxy)ethoxy]ethyl}amino)butan-l-ol
R(-)-2-({2-[2-(2-chloro-6-methylphenoxy)ethoxy]ethyl}amino)butan-l-ol
S-(+)-2-({2-[2-(2-chloro-6-methylphenoxy)ethoxy]ethyl}amino)butan-l-ol
R,S-2-({2-[2-(2-chloro-6-methylphenoxy)ethoxy]ethyl}amino)-4-hydroxypiperidine
R,S-2-({2-[2-(2-chloro-6-methylphenoxy)ethoxy]ethyl}amino)-l-phenylethanol
R,S-2-({2-[2-(2,4,6-trimethylphenoxy)ethoxy]ethyl}amino)propan-l-ol
trans-D,L-2-({2-[2-(2,4,6-trimethylphenoxy)ethoxy]ethyl}amino)cyclohexanol
R,S-2-({2-[2-(2,3-dimethylphenoxy)ethoxy]ethyl}amino)propan-l-ol
trans-D,L-2-({2-[2-(2,3-dimethylphenoxy)ethoxy]ethyl}amino)cyclohexanol
trans-4-({2-[2-(2,3-dimethylphenoxy)ethoxy]ethyl}amino)cyclohexanol
l-{2-[2-(2,3-dimethylphenoxy)ethoxy]ethyl}-4-hydroxypiperidine hydrochloride
R,S-2-({2-[2-(2,4-dimethylphenoxy)ethoxy]ethyl}amino)propan-l-ol.
3. The use of N-[(phenoxy)ethoxy]alkylaminoalkanols with general structure 1, in which Rl means (CH3)2; (CH3)3 or CI and CH3, and R2 means aminoalkanol selected from the group of (R,S)-2- aminopropan-l-ol ; (R)-2-aminopropan- 1 -ol; (S)-2-aminopropan-l-ol; (R,S)-2-aminobutan-l-ol; 2
(R)-2-aminobutan-l-ol; (S)-2-aminobutan-l-ol; trans-(D,L)-2-aminocyclohexanol; trans-4- aminocyclohexanol; (R,S)-2-amino-l -phenyl oethanol; 4-hydroxypiperidine and their salts and prodrugs accepted for use in pharmacotherapy, for preparation of drug used in the therapy and/or prophylaxis of disorders and/or symptoms with neurological etiology, especially epilepsy and/or pain.
PCT/PL2014/050047 2013-08-09 2014-08-07 New derivatives of n-[(phenoxy)ethoxy]alkylaminoalkanols and their use for preparation of drugs WO2015020545A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PLP.405040 2013-08-09
PL405040A PL225258B1 (en) 2013-08-09 2013-08-09 New derivatives of N-[(phenoxy)ethoxy]alkylamino alkanols and their application for manufacturing of medicines

Publications (2)

Publication Number Publication Date
WO2015020545A2 true WO2015020545A2 (en) 2015-02-12
WO2015020545A3 WO2015020545A3 (en) 2015-04-02

Family

ID=51541274

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/PL2014/050047 WO2015020545A2 (en) 2013-08-09 2014-08-07 New derivatives of n-[(phenoxy)ethoxy]alkylaminoalkanols and their use for preparation of drugs

Country Status (2)

Country Link
PL (1) PL225258B1 (en)
WO (1) WO2015020545A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4118511A (en) 1976-05-19 1978-10-03 Ayerst, Mckenna & Harrison Limited Aryloxy aminobutanols for alleviating symptoms of depression
PL212489A1 (en) 1978-12-29 1980-07-01 Zaklady Urzadzen Chem
PL211939A1 (en) 1978-12-19 1980-07-14 Inst Maszyn Spozywczych
EP1809273A2 (en) 2004-09-16 2007-07-25 Janssen Pharmaceutica N.V. Use of 2-phenyl-1,2-ethanediol-(di)carbamates for treating epileptogenesis and epilepsy
PL401500A1 (en) 2012-11-07 2014-05-12 Uniwersytet Jagielloński New alkanolamides cinnamic acid derivatives and the use of cinnamic acid derivatives alkanolamides the preparation of medicaments

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011507910A (en) * 2007-12-21 2011-03-10 ユニバーシティー オブ ロチェスター Methods for changing the lifetime of eukaryotes
PL212489B1 (en) * 2008-01-22 2012-10-31 Univ Jagiellonski Phenoxyalkiloaminoalkanols derivatives and its applications

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4118511A (en) 1976-05-19 1978-10-03 Ayerst, Mckenna & Harrison Limited Aryloxy aminobutanols for alleviating symptoms of depression
PL211939A1 (en) 1978-12-19 1980-07-14 Inst Maszyn Spozywczych
PL212489A1 (en) 1978-12-29 1980-07-01 Zaklady Urzadzen Chem
EP1809273A2 (en) 2004-09-16 2007-07-25 Janssen Pharmaceutica N.V. Use of 2-phenyl-1,2-ethanediol-(di)carbamates for treating epileptogenesis and epilepsy
PL401500A1 (en) 2012-11-07 2014-05-12 Uniwersytet Jagielloński New alkanolamides cinnamic acid derivatives and the use of cinnamic acid derivatives alkanolamides the preparation of medicaments

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BANERJEE, P .N.; FILIPPI, D.; ALLEN HAUSER, W.: "The descriptive epidemiology of epilepsy-a review", EPILEPSY RES., vol. 85, 2009, pages 31 - 45
BIALER, M.; WHITE, H. S.: "Key factors in the discovery and development of new antiepileptic drugs", NATURE REV DRUG DISCOV., vol. 9, 2010, pages 68 - 82
BRODIE, M.J.: "Management strategies for refractory localization-related seizures", EPILEPSIA, vol. 42, no. 3, 2001, pages 27 - 30
CAPONE, F.; ALOISI, A. M.: "Annali dell'Istituto Superiore di Sanità", vol. 40, 2004, article "Refinement of pain evaluation techniques. The formalin test", pages: 223 - 229
H. MARONA; A.M. WASZKIELEWICZ; E. SZNELER, ACTA POL. PHARM., vol. 62, no. 5, 2005, pages 345 - 353
H. MARONA; L. ANTKIEWICZ-MICHALUK, ACTA POL. PHARM., vol. 55, no. 6, 1998, pages 487 - 498
L6SCHER, W.: "Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs", SEIZURE, vol. 20, 2011, pages 359 - 368
WASZKIELEWICZ A. M.; GUNIA A.; SLOCZYNSKA K .; MARONA H.: "Evaluation of anticonvulsants for possible use in neuropathic pain", CURR MED CHEM., vol. 18, 2011, pages 4344 - 4358
WHITE, H. S.; WOODHEAD, J. H.; WILCOX, K. S.; STABLES, J. P.; KUPFERBERG, H. J.; WOLF, H. H. D.: "W: Antiepileptic Drugs", 2002, LIPPINCOTT WILLIAMS & WILKINS, article "Discovery and preclinical development of antiepileptic drugs", pages: 36 - 48

Also Published As

Publication number Publication date
WO2015020545A3 (en) 2015-04-02
PL225258B1 (en) 2017-03-31
PL405040A1 (en) 2015-02-16

Similar Documents

Publication Publication Date Title
US8841347B2 (en) Derivatives of aminoalkanols, method of obtaining of aminoalkanols and their use
US20090082464A1 (en) Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
US10738017B2 (en) Substituted triazoles and methods relating thereto
US8518979B2 (en) Alpha-halo- and alpha-alkyl-cyclopropylcarboxy compounds and uses thereof
CZ126598A3 (en) Phenylethanolamine compounds, process of their preparation and pharmaceutical compositions containing thereof
EP3778579A1 (en) Aromatic compound and preparation method therefor and use thereof
CN105189450A (en) Phenyl carbamate compound and a composition for preventing or treating a psychiatric disorder comprising the same
DE69818516T2 (en) PHENYLAMINOALKYL ACID ACID DERIVATIVES AND MEDICAL COMPOSITIONS CONTAINING THEM
EP0239815A1 (en) Substituted thiazoles and oxazoles, medicines containing these compounds and process for their preparation
WO2015020545A2 (en) New derivatives of n-[(phenoxy)ethoxy]alkylaminoalkanols and their use for preparation of drugs
DE69919860T2 (en) 2-METHYLPROPIONIC ACID DERIVATIVES AND MEDICAL PREPARATIONS CONTAINING THEM
EA022158B1 (en) Modulators of fatty acid amide hydrolase activity
US20200181067A1 (en) Fluorinated amide derivatives and their uses as therapeutic agents
US11168052B2 (en) Carbamate derivative compounds, processes for preparing them and their uses
Krishna Prasad et al. Design and synthesis of novel 2-(5-(4-aryl)-4, 5-dihydro-1 H-pyrazol-3-yl)-1-(substituted aminomethyl)-1 H-benzimidazole as potent anticonvulsants
WO2024026574A1 (en) 3-pyrrolidine-indole dimers as serotonergic agents useful for the treatment of disorders related thereto
DE3729284A1 (en) NEW HETEROARYLETHANOLAMINES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
PL220733B1 (en) New alkanolamides cinnamic acid derivatives and the use of cinnamic acid derivatives alkanolamides the preparation of medicaments

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14766238

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14766238

Country of ref document: EP

Kind code of ref document: A2